Vertex Pharmaceuticals (VRTX) said Monday that the European Commission has expanded the label for Kaftrio in cystic fibrosis to include patients 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator gene.
The company said around 4,000 cystic fibrosis patients in the European Union are now eligible to receive the medicine.
Kaftrio, or ivacaftor/tezacaftor/elexacaftor, is administered in combination with ivacaftor to treat cystic fibrosis patients.
Vertex said eligible patients in Austria, Denmark, Ireland, Norway, Sweden and Germany are expected to have access to Kaftrio "shortly."
Price: 469.03, Change: -5.59, Percent Change: -1.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.